Therapeutic drug monitoring during OPAT

"We describe early experience with beta-lactam therapeutic drug monitoring (TDM) in a high-volume outpatient parenteral antimicrobial therapy program" Barrett et al (2026).

"We describe early experience with beta-lactam therapeutic drug monitoring (TDM) in a high-volume outpatient parenteral antimicrobial therapy program" Barrett et al (2026).

ReTweet

Therapeutic drug monitoring during OPAT

Abstract:

We describe early experience with beta-lactam therapeutic drug monitoring (TDM) in a high-volume outpatient parenteral antimicrobial therapy program. In selected patients, TDM informed dose optimization and toxicity mitigation. Illustrative cases highlight feasibility and emerging lessons supporting beta-lactam TDM in outpatient care.

Reference:

Barrett KO, Rivera CG, Abu Saleh O, Pertzborn M, Ausman SE, Rule AD, Arensman Hannan K, Stevens RW, Barreto EF. Early Experience With Beta-Lactam Therapeutic Drug Monitoring in an Outpatient Parenteral Antimicrobial Therapy (OPAT) Program. Open Forum Infect Dis. 2026 May 25;13(5):ofag299. doi: 10.1093/ofid/ofag299. PMID: 42221364; PMCID: PMC13218442.